Clinical Trial Update: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CB-839 in combination with nivolumab in melanoma, clear cell renal cell carcinoma, and non-small cell lung cancer (Phase 1/Phase 2) ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CB-839 (telaglenastat)
• nivolumab (nivolumab)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-17